Pharmacokinetics Program
药代动力学程序
基本信息
- 批准号:8738006
- 负责人:
- 金额:$ 0.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntineoplastic AgentsBiologicalCancer CenterCancer Center Support GrantChildClinicalCollaborationsCollectionDiscipline of NursingDrug KineticsEnsureEquipmentFundingIntranetLaboratoriesLeadershipMissionPeer ReviewPharmacodynamicsPhasePre-Clinical ModelProceduresProcessQuality ControlResearch DesignResource SharingResourcesSaint Jude Children&aposs Research HospitalSamplingServicesSiteSystemTestingTranslational Researchcostindexingpharmacodynamic modelpharmacokinetic modelpreclinical studyprograms
项目摘要
Since the founding of the Pharmacokinetics Shared Resource in 1983, the primary mission of the Core has
been to facilitate high-quality competitively funded peer-reviewed pharmacokinetic/pharmacodynamic
translational research in both clinical and pre-clinical models at the SJ Cancer Center. The objectives are to 1)
implement trials with pharmacokinetic studies at the St. Jude Cancer center by assisting with study design,
building of standard orders and laboratory test procedures, and educating nursing and other clinical staff 2)
efficiently and properly collect, accession, process, and distribute pharmacokinetic samples on these trials and
3) ensure valid, high quality sensitive and specific analyses of anticancer drugs, their metabolites, or other
relevant pharmacologic indices in biological samples, and assist with state-of-the-art biomedical
pharmacokinetic and pharmacodynamic modelling. The benefits of the Pharmacokinetics Shared Resource to
the Cancer Center include: cost-efficiency, consistency in application of state-of-the-art equipment, facilities,
and approaches to pharmacokinetic/dynamic projects, standardized operating procedures for regimented,
continuous, and thoroughly documented analytical quality control, centralized sample processing and storage,
consolidation of resources in a single facility, minimization of invasive collection procedures in children and
minimizing the number of animals for preclinical studies, and stimulation of scientific collaborations.
Since the last competitive renewal, the LC-MS capacity of the Shared Resource has been greatly enhanced. A
chargeback system was begun and is being phased in to apply to all samples processed by the Resource. An
intranet site was established with clear explanations for chargebacks and services provided, Dr. Crews joined
the shared resource in July 2005 as Co-Director to supervise the day-to-day activities of the core. Dr. Baker
joined the core in August 2006 and will take over as Director of the shared resource for this renewal
application; Dr. Relling will remain involved as a consultant to ensure a seamless transition in leadership.
自1983年药代动力学共享资源成立以来,核心的主要使命为
促进高质量的竞争性资助的同行评审药代动力学/药效学
SJ癌症中心的临床和临床前模型转化研究。目标是:(1)
通过协助研究设计,在圣犹达癌症中心实施药代动力学研究试验,
建立标准医嘱和实验室检测程序,并对护理和其他临床工作人员进行教育2)
有效和适当地收集、登记、处理和分发这些试验的药代动力学样本,
3)确保对抗癌药物、其代谢物或其他药物进行有效、高质量的灵敏度和特异性分析,
生物样品中的相关药理学指标,并协助最先进的生物医学
药代动力学和药效学建模。药代动力学共享资源的益处,
癌症中心包括:成本效益,最先进设备、设施
药代动力学/动力学项目的方法,
连续的、完整记录的分析质量控制,集中的样品处理和储存,
将资源集中在一个设施内,尽量减少对儿童的侵入性采集程序,
最大限度地减少用于临床前研究的动物数量,并促进科学合作。
自上次竞争性更新以来,共享资源的LC-MS容量已大大增强。一
收费系统已经启动,正在分阶段实施,以适用于资源公司处理的所有样品。一个
Crews博士加入了一个内联网网站,其中明确解释了退款和提供的服务
2005年7月,作为共同主任使用共享资源,监督核心小组的日常活动。贝克博士
我于2006年8月加入核心,并将接任此次更新的共享资源主任
Relling博士将继续作为顾问参与,以确保领导层的无缝过渡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sharyn D Baker其他文献
Sharyn D Baker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sharyn D Baker', 18)}}的其他基金
Targeting neuronal transport to ameliorate vincristine neurotoxicity
靶向神经元运输以改善长春新碱神经毒性
- 批准号:
10736789 - 财政年份:2023
- 资助金额:
$ 0.08万 - 项目类别:
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN
ETCTN 的切萨皮克-俄亥俄药代动力学核心
- 批准号:
10560616 - 财政年份:2020
- 资助金额:
$ 0.08万 - 项目类别:
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN
ETCTN 的切萨皮克-俄亥俄药代动力学核心
- 批准号:
10361549 - 财政年份:2020
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
8961350 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
7888591 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
8207924 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
8042706 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
8599751 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
Tyrosine kinase inhibitors for the treatment of childhood AML
酪氨酸激酶抑制剂用于治疗儿童 AML
- 批准号:
8404027 - 财政年份:2010
- 资助金额:
$ 0.08万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 0.08万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 0.08万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 0.08万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 0.08万 - 项目类别:














{{item.name}}会员




